Last reviewed · How we verify
Niacin plus laropiprant
Niacin plus laropiprant is a Lipid-modifying agent combination Small molecule drug developed by Institut Investigacio Sanitaria Pere Virgili. It is currently FDA-approved for Dyslipidemia and mixed dyslipidemia in patients at risk for cardiovascular disease. Also known as: Tredaptive.
Niacin raises HDL cholesterol and lowers triglycerides, while laropiprant blocks prostaglandin D2 receptors to reduce niacin-induced flushing.
Niacin combined with laropiprant is used to treat conditions such as primary hypercholesterolaemia, mixed hyperlipidaemia, and dyslipidemia. The mechanism of action of laropiprant involves antagonizing the prostaglandin D2 receptor, a prostanoid DP receptor.
At a glance
| Generic name | Niacin plus laropiprant |
|---|---|
| Also known as | Tredaptive |
| Sponsor | Institut Investigacio Sanitaria Pere Virgili |
| Drug class | Lipid-modifying agent combination |
| Target | DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Niacin (vitamin B3) is a lipid-modifying agent that increases HDL cholesterol and decreases triglycerides and LDL cholesterol through multiple pathways including inhibition of hepatic VLDL production. Laropiprant is a selective antagonist of the prostaglandin D2 receptor (DP1), which mitigates the vasodilatory flushing side effect that limits niacin tolerability and compliance.
Approved indications
- Dyslipidemia and mixed dyslipidemia in patients at risk for cardiovascular disease
Common side effects
- Flushing
- Pruritus
- Gastrointestinal upset
- Hyperglycemia
- Hepatotoxicity
Key clinical trials
- Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) (PHASE3)
- Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease (PHASE4)
- A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED) (PHASE1)
- ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (PHASE4)
- Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome (PHASE4)
- MK-0524B Lipid Study (MK-0524B-063) (PHASE3)
- Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (PHASE3)
- Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niacin plus laropiprant CI brief — competitive landscape report
- Niacin plus laropiprant updates RSS · CI watch RSS
- Institut Investigacio Sanitaria Pere Virgili portfolio CI
Frequently asked questions about Niacin plus laropiprant
What is Niacin plus laropiprant?
How does Niacin plus laropiprant work?
What is Niacin plus laropiprant used for?
Who makes Niacin plus laropiprant?
Is Niacin plus laropiprant also known as anything else?
What drug class is Niacin plus laropiprant in?
What development phase is Niacin plus laropiprant in?
What are the side effects of Niacin plus laropiprant?
What does Niacin plus laropiprant target?
Related
- Drug class: All Lipid-modifying agent combination drugs
- Target: All drugs targeting DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways
- Manufacturer: Institut Investigacio Sanitaria Pere Virgili — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Dyslipidemia and mixed dyslipidemia in patients at risk for cardiovascular disease
- Also known as: Tredaptive
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing